New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra)

CMAJ. Canadian Medical Association Journal

Volumn 172, Issue 10, 2005, Pages 1299-

  Cotter, Jill ^a   Wooltorton, Eric ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; IBUPROFEN; INDOMETACIN; KETOROLAC; MELOXICAM; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SULINDAC; VALDECOXIB;

CARDIOTOXICITY; ERYTHEMA MULTIFORME; GASTROINTESTINAL TOXICITY; HUMAN; OSTEOARTHRITIS; RISK BENEFIT ANALYSIS; SHORT SURVEY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 19744365338     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.050456     Document Type: Short Survey

References (3)

1. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
2. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the Cox-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
3. Health Canada. Health Canada endorsed important safety information on BEXTRA (valdecoxib) tablets [letter]. Dec. 10, 2004. Available at www.hc-sc .gc.ca/hpfb-dgpsa/tpd-dpt/bextra2_hpc_e.html (accessed 2005 Apr 14).